NCT06109207 2024-07-23
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
Clinical Trials
5 trialsNCT05798793 2024-04-02
NEOPCOSCC
Hospital of Stomatology, Wuhan University
Phase 3 Recruiting
NCT05069857 2023-11-22
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT05213884 2023-05-06
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT04826679 2021-04-01
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Sun Yat-sen University
Phase 2 Recruiting